These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21771206)

  • 21. Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors--a thrombin generation-guided pilot study.
    Livnat T; Martinowitz U; Azar-Avivi S; Zivelin A; Brutman-Barazani T; Lubetsky A; Kenet G
    Haemophilia; 2013 Sep; 19(5):782-9. PubMed ID: 23659442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.
    Astermark J; Rocino A; Von Depka M; Van Den Berg HM; Gringeri A; Mantovani LG; Morado M; Garrido RP; Schiavoni M; Villar A; Windyga J;
    Haemophilia; 2007 Jan; 13(1):38-45. PubMed ID: 17212723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic.
    Salaj P; Brabec P; Penka M; Pohlreichova V; Smejkal P; Cetkovsky P; Dusek L; Hedner U
    Haemophilia; 2009 May; 15(3):752-9. PubMed ID: 19432926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors.
    Hay JW; Zhou ZY
    Haemophilia; 2011 Sep; 17(5):e969-74. PubMed ID: 21649802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient- and caregiver-reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: analysis of the Dosing Observational Study in Haemophilia (DOSE).
    Valentino LA; Walsh CE; Reding MT; Young GA; Levendoglu-Tugal O; Cooper DL
    Haemophilia; 2012 Jul; 18(4):554-60. PubMed ID: 22348407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single higher dose of recombinant activated factor VII in the treatment of hemorrhages in patients with hemophilia complicated by inhibitors.
    Łaguna P; Mital A
    Adv Clin Exp Med; 2012; 21(4):519-24. PubMed ID: 23240458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant activated factor VII safety and efficacy in the treatment of cranial haemorrhage in patients with congenital haemophilia with inhibitors: an analysis of the Hemophilia and Thrombosis Research Society Registry (2004-2008).
    Nakar C; Cooper DL; DiMichele D
    Haemophilia; 2010 Jul; 16(4):625-31. PubMed ID: 20158526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors.
    Joshi AV; Stephens JM; Munro V; Mathew P; Botteman MF
    Curr Med Res Opin; 2006 Jan; 22(1):23-31. PubMed ID: 16393427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors.
    Qi X; Zhao Y; Li K; Fan L; Hua B
    Blood Coagul Fibrinolysis; 2014 Oct; 25(7):754-60. PubMed ID: 24806320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries.
    Bensadok M; Almomen A; Alzoebie A; Benchikh El Fegoun S; Wali Y; Hamzy F; Mehalhal NG; Grifi F; Hamdi S; Mesli N; Owaidah T; Saad HA; Mansour NS; Touhami H
    Blood Coagul Fibrinolysis; 2017 Mar; 28(2):145-151. PubMed ID: 27100303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors.
    Hay JW; Chaugule SC; Young G
    Haemophilia; 2013 Sep; 19(5):711-9. PubMed ID: 23672765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of the UKHCDO Database for a postmarketing surveillance study of different doses of recombinant factor VIIa in haemophilia.
    Hay CRM; Sharpe T; Dolan G;
    Haemophilia; 2017 May; 23(3):376-382. PubMed ID: 28026073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The evidence behind inhibitor treatment with recombinant factor VIIa.
    Ludlam CA
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():13-8. PubMed ID: 12214140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil.
    Ozelo MC; Villaça PR; De Almeida JO; Bueno TM; De Miranda PA; Hart WM; Karamalis M
    Haemophilia; 2007 Sep; 13(5):462-9. PubMed ID: 17880430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors.
    Šalek SZ; Auerswald G; Benson G; Dolan G; Duffy A; Hermans C; Jiménez-Yuste V; Ljung R; Morfini M; Santagostino E; Lambert T
    Blood Transfus; 2017 Jan; 15(1):77-84. PubMed ID: 26674816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of recombinant factor VIIa administered by continuous infusion to haemophilia patients with inhibitors.
    Mauser-Bunschoten EP; Koopman MM; Goede-Bolder AD; Leebeek FW; van der Meer J; van Marwijk Kooij GM; van der Linden PW;
    Haemophilia; 2002 Sep; 8(5):649-56. PubMed ID: 12199674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overall experience with NovoSeven.
    Négrier C; Lienhart A
    Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S19-24. PubMed ID: 10850559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NovoSeven in immune tolerance therapy.
    Brackmann HH; Effenberger E; Hess L; Schwaab R; Oldenburg J
    Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S39-44. PubMed ID: 10850563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study.
    Macik BG; Lindley CM; Lusher J; Sawyer WT; Bloom AL; Harrison JF; Baird-Cox K; Birch K; Glazer S; Roberts HR
    Blood Coagul Fibrinolysis; 1993 Aug; 4(4):521-7. PubMed ID: 8218848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intestinal surgery with activated recombinant factor VII prophylaxis in patients with haemophilia A and high responding inhibitors: a report of five cases.
    Slaoui M; Lambert T; Stieltjes N; Claeyssens S; Borel-Derlon A;
    Blood Coagul Fibrinolysis; 2004 Oct; 15(8):687-91. PubMed ID: 15613924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.